logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q2 2020
Akero Therapeutics Inc.
Full data readout from phase IIa study of AKR-001 (BALANCED)
Non-alcoholic steatohepatitis
Q2 2020
Oncolytics Biotech
ONC.TO, ONCY
Final data from phase Ib window of opportunity study assessing Pelareorep with or without Roche's Tecentriq (AWARE-1)
breast cancer
Q2 2020
ObsEva SA
6-month primary endpoint data from phase III clinical trial of Linzagolix (PRIMROSE1)
Heavy menstrual bleeding due to uterine fibroids
Q2 2020
Foamix Pharmaceuticals Ltd.
Topline data from phase II trial of FCD105
moderate-to-severe acne vulgaris.
Q2 2020
Blueprint Medicines
Top-line from phase III VOYAGER trial
Fourth-line gastrointestinal stromal tumors (GIST)
Q2 2020
IDEAYA Biosciences
Interim data from phase I/II basket trial of IDE196
Ssolid tumors harboring GNAQ/11 mutations or PRKC fusions
Q2 2020
Akebia Therapeutics, Inc.
Top-line data from Two global phase III studies of Vadadustat ( INNO2VATE)
Dialysis-dependent chronic kidney disease (CKD) subjects with anemia due to CKD
Q2 2020
Myovant Sciences Ltd
Data from 2nd phase III trial of Relugolix (SPIRIT 2)
Endometriosis-associated pain in Women
Q2 2020
SOLIGENIX, INC.
Final results from phase III study of SGX942 (dusquetide)
Oral mucositis in patients with head and neck cancer
Q2 2020
Catabasis Pharmaceuticals, Inc.
Top-line results from phase III trial of Edasalonexent (POLARIS DMD)
Duchenne muscular dystrophy
Mar 2020
Immutep Limited
Data read-out from phase IIb clinical trial of Eftilagimod alpha in combination with Paclitaxel(AIPAC)
Metastatic breast cancer
19-Feb-2020 To 23-Feb-2020
Kadmon Holdings LLC
Data from primary analysis of open-label registration trial of KD025 (KD025-213)
Chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of systemic therapy
13-Feb-2020
Advaxis Inc.
Data from Phase 1/2 clinical trial of ADXS-PSA as standalone, or monotherapy, and in combination with Keytruda (KEYNOTE-046)
Metastatic castration-resistant prostate cancer,
13-Feb-2020
TrovaGene Inc.
New data from phase II study of Onvansertib
Metastatic castrate-resistant prostate cancer
06-Feb-2020 To 08-Feb-2020
Forty Seven, Inc.
Data from Phase 1b trial of 5F9 in combination with avelumab
Ovarian cancer
Mid Feb 2020
Immutep Limited
Mature data from phase II study of Eftilagimod Alpha in combination with Keytruda (TACTI-002)
Non-small cell lung carcinoma and head and neck carcinoma
Feb 2020
CTD Holdings Inc
CTDH.OB
Data from Phase I trial of Trappsol
Niemann-Pick Disease Type C
31-Jan-2020
MIRAGEN THERAPEUTICS, INC.
New efficacy and safety data from Phase 1 trial of cobomarsen
T-cell leukemia/lymphoma (ATLL) in adults
24-Jan-2020
Bellicum Pharmaceuticals, Inc
New translational data from cohort 5B in phase I/II trial of BPX-601
Pancreatic, gastric, or prostate cancers expressing prostate stem cell antigen, or PSCA
23-Jan-2020 To 25-Jan-2020
Forty Seven, Inc.
Initial data from phase Ib/II trial of Magrolimab in combination with Cetuximab
Colorectal cancer
23-Jan-2020
Applied Genetic Technologies Corp.
Interim six-month data from parallel phase I/II studies of gene therapy(CNGB3 trial)
Achromatopsia
23-Jan-2020
Applied Genetic Technologies Corp.
Interim six-month data from parallel phase I/II studies of gene therapy(CNGA3 trial)
Achromatopsia
13-Jan-2020
Verona Pharma plc
Results from phase IIb trial of nebulized Ensifentrine as an add-on to inhaled tiotropium
Chronic obstructive pulmonary disease
09-Jan-2020
Applied Genetic Technologies Corp.
Interim 6-month data from expansion group of a phase I/II study of gene therapy
X-linked Retinitis Pigmentosa
Q1 2020
Axsome Therapeutics, Inc.
Topline data from a phase III trial of AXS-07 ( INTERCEPT)
Migraine
>